MaxisIT launches a new logo. Introduces AI into its products and services
MaxisIT launches a new logo. Introduces AI into its products and services
Now get Data, Analytics, Insights faster with the power of AI
METUCHEN, N.J. – Oct. 25, 2019 – PRLog — MaxisIT, a premier provider of a true cloud-based integrated platform solution for clinical drug development, is introducing artificial intelligence (AI) to its products and services.
The new AI-based end-to-end clinical development platform promises to
· Deliver action-oriented Intelligence via Artificial Intelligence
· Advance (“>”) the clinical development to enable faster patient care
· Empower the patients and clinical trials stakeholders via reduced “IT” intervention in a true self-service era.
Speaking to us, Maulik Shah, CEO, MaxisIT says “We are driven to enable pharma and biotech companies to develop safe and effective drugs faster as well as deliver care to the patients in need. Our new AI-powered platform will empower the clinical trials’ stakeholders to make decisions faster based on action-oriented intelligence delivered to them in real-time ”
With the introduction of AI to its offerings, MaxisIT reinforces its position as an industry innovator in cloud-based clinical data and analytics software platform for the pharmaceutical industry. Visit https://maxisit.com
MaxisIT helps pharmaceutical and biopharmaceutical companies of all sizes plan and execute effective clinical trials. Our source-agnostic integrated clinical data analytics platform unifies data across clinical systems and CROs to enable real-time monitoring and on-time insights.